NCT02706535: A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential |
|
|
| Completed | 1 | 29 | US | GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg | GlaxoSmithKline | Drug Interactions, Neoplasms | 01/17 | 01/17 | | |
NCT03925428: Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas |
|
|
| Withdrawn | 1 | 0 | NA | Entinostat, HDAC inhibitor SNDX-275, MS 27-275, MS-275, SNDX-275, Molibresib, GSK-525762A, GSK525762, I-BET 762 | National Cancer Institute (NCI) | Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma | 09/20 | 09/20 | | |
